PharmaCyte Biotech on Track for 2016 Cancer Clinical Trial in Pancreatic Cancer

PharmaCyte Biotech, Inc. (OTCQB:PMCB) issued a further update on its upcoming clinical trial in pancreatic cancer.
According to PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner:

PharmaCyte is involved in a well-planned, detailed and methodical process to insure that every aspect of the IND is correct before we submit the IND to the FDA. As the “Sponsor” of the IND, it is our responsibility to insure that the Chemistry, Manufacturing and Controls (CMC) section of the IND is complete and accurate in every respect. We are working with Translational Drug Development (TD2), Chamow & Associates (Chamow) and Austrianova in completing everything that is required. It is a process that began last year and is well underway.

Click here to view the full press release.